Malin Corp PLC - Dublin-based investor in life sciences companies - Reports intrinsic equity value of €6.44 at June 30 half-year end, down 1.8% from €6.56 at end of December. Declines further to €6.33 as at August 22. Attributes decline to lower Poseida share price and a downward revision of its interest in Viamet. Says further studies by Viament on Vivjoa have delayed commercial launches and associated royalties as Viament seeks to receive extended approval for Vivjoa. ‘We expect further clarity on the future regulatory, commercial and strategic pathway in the months ahead,’ Malin says. Further, cash position at August 22 increases to €62.9 million, from €35.7 million at end of June, owing to its divestment of CG Oncology, company says. Divestment generated cash proceeds of about €28.5 million, a 175% gain on total capital invested.

Current share price: €5.90

12-month change: up 28%

Copyright 2024 Alliance News Ltd. All Rights Reserved.